by telrheum | Dec 3, 2024 | Connective Tissue Diease, Anti-Synthetase Syndrome, Interstitial Lung Disease, Systemic Sclerosis
The “Classification Criteria for Anti-Synthetase Syndrome (CLASS) Project” sought to develop new, standardized guidelines to diagnose Anti-Synthetase Syndrome (ASSD), a rare autoimmune condition that primarily affects muscles, joints, and lungs and is linked to...
by telrheum | Sep 9, 2024 | Autoimmune Diseases, Interstitial Lung Disease, Sjögren’s Syndrome
This study explores whether the presence of certain antibodies (anti-SSa and Ro52) affects the progression of lung disease (interstitial lung disease or ILD) in people with idiopathic inflammatory myopathies (IIM). These antibodies are often found in individuals with...
by telrheum | Aug 9, 2024 | Autoimmune Diseases, Connective Tissue Diease, Interstitial Lung Disease, Rheumatoid Arthritis, Sjögren’s Syndrome, Systemic Sclerosis
This study focuses on a treatment for patients with connective tissue diseases (CTD) who also have a lung condition called interstitial lung disease (ILD). This condition, when it becomes progressive and fibrosing (PF-ILD), can lead to serious lung damage. The...
by telrheum | Jun 25, 2024 | Psoriatic Arthritis, Interstitial Lung Disease, Rheumatoid Arthritis, Spondyloarthritis
Background and Purpose: Pulmonary issues are common yet often overlooked in people with rheumatic diseases like rheumatoid arthritis (RA), psoriatic arthritis (PsA), and peripheral spondyloarthritis (pSpA). These lung problems can lead to severe health consequences if...
by telrheum | May 25, 2024 | Interstitial Lung Disease, JAK Inhibitor, Systemic Sclerosis
This study explored the effectiveness and safety of nintedanib (NTB), a drug approved for progressive fibrosing interstitial lung disease (PF-ILD), in combination with immunosuppressive agents (IS) for treating connective tissue disease-associated PF-ILD (CTD-PF-ILD)....
